BR112021000391A2 - Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4 - Google Patents

Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4 Download PDF

Info

Publication number
BR112021000391A2
BR112021000391A2 BR112021000391-6A BR112021000391A BR112021000391A2 BR 112021000391 A2 BR112021000391 A2 BR 112021000391A2 BR 112021000391 A BR112021000391 A BR 112021000391A BR 112021000391 A2 BR112021000391 A2 BR 112021000391A2
Authority
BR
Brazil
Prior art keywords
domain
monomer
polypeptide
fact
construct
Prior art date
Application number
BR112021000391-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Elma KURTAGIC
Laura RUTITZKY
Daniel Ortiz
Jonathan C. Lansing
Anthony Manning
Original Assignee
Momenta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals, Inc. filed Critical Momenta Pharmaceuticals, Inc.
Publication of BR112021000391A2 publication Critical patent/BR112021000391A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112021000391-6A 2018-07-11 2019-07-11 Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4 BR112021000391A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696746P 2018-07-11 2018-07-11
US62/696,746 2018-07-11
PCT/US2019/041324 WO2020014429A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4

Publications (1)

Publication Number Publication Date
BR112021000391A2 true BR112021000391A2 (pt) 2021-04-06

Family

ID=69142497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000391-6A BR112021000391A2 (pt) 2018-07-11 2019-07-11 Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4

Country Status (11)

Country Link
US (1) US20250346676A1 (https=)
EP (1) EP3820517A4 (https=)
JP (1) JP2021531756A (https=)
KR (1) KR20210042324A (https=)
CN (1) CN113164590A (https=)
AU (1) AU2019302662A1 (https=)
BR (1) BR112021000391A2 (https=)
CA (1) CA3105985A1 (https=)
IL (1) IL279987A (https=)
MX (1) MX2021000290A (https=)
WO (1) WO2020014429A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers
MX2024008641A (es) * 2022-01-12 2024-07-24 Biomolecular Holdings Llc Anticuerpos tetraedricos.
CN121100128A (zh) * 2023-04-24 2025-12-09 百图生科(苏州)智能科技有限公司 异源多聚体多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
WO2009086514A1 (en) * 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
EP3511343A1 (en) * 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
EP3423572B1 (en) * 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs

Also Published As

Publication number Publication date
WO2020014429A2 (en) 2020-01-16
KR20210042324A (ko) 2021-04-19
US20250346676A1 (en) 2025-11-13
CN113164590A (zh) 2021-07-23
CA3105985A1 (en) 2020-01-16
EP3820517A4 (en) 2022-04-06
AU2019302662A1 (en) 2021-02-25
JP2021531756A (ja) 2021-11-25
WO2020014429A3 (en) 2020-02-13
MX2021000290A (es) 2021-09-08
EP3820517A2 (en) 2021-05-19
IL279987A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
US11827682B2 (en) Engineered Fc constructs
BR112021000427A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ctla-4
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
BR112021000416A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a cd38
BR112021000391A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ccr4
BR112021000383A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a pd-l1
BR112021000415A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
BR112021000393A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado
BR112021000388A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado
CA3049383C (en) Compositions and methods related to engineered fc constructs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2783 DE 07-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.